Fixed-Ratio Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus Treatment in Type 2 Diabetic (T2DM) Patients with Diabetic Foot Ulcers (DFU) and Critical Limb Ischemia (CLI)

被引：0

|

作者：

Falcetta, Pierpaolo

Indovina, Francesco S.

Giannarelli, Rosa

Piaggesi, Alberto

Penno, Giuseppe

Miccoli, Roberto

Del Prato, Stefano

Coppelli, Alberto

机构：

来源：

DIABETES | 2019年 / 68卷

关键词：

D O I：

10.2337/db19-2256-PUB

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2256-PUB

引用

收藏

页数：2

相关论文

共 33 条

[31] Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
Gough, Stephen C. L.
Bode, Bruce
Woo, Vincent
Rodbard, Helena W.
Linjawi, Sultan
Poulsen, Pernille
Damgaard, Lars H.
Buse, John B.
LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (11): : 885 - 893
[32] Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)-DUAL IX Trial
Philis-Tsimikas, Athena
Billings, Liana
Busch, Robert S.
Portillo, Cristobal Morales
Sahay, Rakesh
Halladin, Natalie
Juhl, Ruta Gronskyte
Harris, Stewart
DIABETES, 2018, 67
[33] Patient-Reported Outcomes (PROs) for Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)-DUAL IX Trial
Brod, Meryl
Billings, Liana K.
Busch, Robert S.
Harris, Stewart
Portillo, Cristobal Morales
Sahay, Rakesh
Busk, Anne
Eggert, Sarah
Halladin, Natalie
Philis-Tsimikas, Athena
DIABETES, 2018, 67

← 1 2 3 4 →